Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.

Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.

Medtech Insight’s new series Getting Personal features conversations with new and veteran senior executives about their journeys to corporate leadership, their motivations, passions and the peaks and valleys of running a medtech company. Daniel Hawkins, founder and CEO of Avail Medsystems discussed how his company virtually connects health care professionals into the operating suite and allows for real-time collaboration.

In following his passion to make an impact in clinical outcomes, Todd Brinton has been back-and-forth across the medtech map since leaving university. Now in a senior role at Edwards Lifesciences, he is not letting up on his quest to continuously innovate and make a difference in clinical care.